Ken Anderson M.D., Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center at Dana-Farber Cancer Institute (DFCI) Discusses RRMM, Carfilzomib, Ixazomib, MyDRUG Trial at Lymphoma & Myeloma on October 18, 2018.
Advertisement